Edition:
United Kingdom

People: Audentes Therapeutics Inc (BOLD.OQ)

BOLD.OQ on NASDAQ Stock Exchange Global Market

37.90USD
19 Jul 2019
Change (% chg)

$-0.18 (-0.47%)
Prev Close
$38.08
Open
$38.16
Day's High
$38.49
Day's Low
$37.52
Volume
110,051
Avg. Vol
154,740
52-wk High
$42.48
52-wk Low
$18.00

Holles, Natalie 

Ms. Natalie C. Holles is President, Chief Operating Officer of the AUDENTES THERAPEUTICS, INC. She previously served as our Senior Vice President, Chief Operating Officer since August 2015. Previously, Ms. Holles served as Senior Vice President, Corporate Development at Hyperion Therapeutics, Inc., a rare disease pharmaceutical company, from June 2013 through its acquisition by Horizon Pharma, plc in May 2015. From August 2012 until June 2013, Ms. Holles served as the Executive Vice President, Corporate Development at Immune Design, Inc., an immunotherapy company, and from December 2010 to June 2013, Ms. Holles served as an independent life sciences corporate development consultant. Earlier in her career, Ms. Holles served as the Vice President, Business Development at KAI Pharmaceuticals, Inc., which was acquired by Amgen in 2012, and previously held corporate development and commercial roles at InterMune, Inc. and Genentech, Inc. Ms. Holles holds an A.B. from Stanford University and an M.A. in molecular, cellular and developmental biology from the University of Colorado, Boulder, where she was a Howard Hughes Medical Institute Predoctoral Fellow.

Basic Compensation

Total Annual Compensation, USD 448,211
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 775,213
Fiscal Year Total, USD 1,223,420

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised 5,090 178,125.00